UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 1
TO
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANTORY NOTE
The purpose of this Amendment No. 1 to the Current Report on Form 8-K filed by Tonix Pharmaceuticals Holding Corp. (the “Company”) on June 13, 2024 (the "Original 8-K"), is solely to replace the Exhibit 5.2 opinion filed therewith which was inadvertently filed with the Exhibit 5.2 opinion filed below. The correct opinion is filed as Exhibit 5.2 hereto and supersedes and replaces in its entirety the opinion filed as Exhibit 5.2 to the Original 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) |
Exhibit No. |
Description. | |
| 1.01 | Placement Agency Agreement, dated June 12, 2024, between Tonix Pharmaceuticals Holding Corp. and Dawson James Securities Inc. (incorporated by reference to Exhibit 1.01 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 4.01 | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.01 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 4.02 | Warrant Agent Agreement, dated June 13, 2024, between Tonix Pharmaceuticals Holding Corp. and VStock Transfer (incorporated by reference to Exhibit 4.02 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 5.01 | Opinion of Brownstein Hyatt Farber Schreck, LLP (incorporated by reference to Exhibit 5.01 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 5.02 | Opinion of Lowenstein Sandler LLP | ||
| 23.01 | Consent of Brownstein Hyatt Farber Schreck, LLP (incorporated by reference to Exhibit 23.01 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 23.02 | Consent of Lowenstein Sandler LLP (contained in Exhibit 5.02) | ||
| 99.01 | Press Release, dated June 11, 2024 (incorporated by reference to Exhibit 99.01 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 99.02 | Press Release, dated June 12, 2024 (incorporated by reference to Exhibit 99.02 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 99.03 | Press Release, dated June 13, 2024 (incorporated by reference to Exhibit 99.03 to the Company’s Current Report on Form 8-K filed on June 13, 2024) | ||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| TONIX PHARMACEUTICALS HOLDING CORP. | |||
| Date: June 14, 2024 | By: | /s/ Bradley Saenger | |
| Bradley Saenger | |||
| Chief Financial Officer | |||